IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to Generic TOVIAZ® 4 Mg and 8 Mg

Published: Jul 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with TOVIAZ® (fesoterodine fumarate extended-release tablets, 4 mg and 8 mg).

Help employers find you! Check out all the jobs and post your resume.

Back to news